City of Hope vice provost to focus on faculty growth initiatives

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Arti Hurria, City of Hope’s new vice provost, plans to focus on faculty growth and development, including fostering faculty career development and ensuring more diverse voices are represented.

Hurria, a geriatrician and oncologist who has been at City of Hope for 10 years, is also its director of Cancer and Aging Research Program. As vice provost, she will have primary oversight of academic and faculty affairs for physicians in the clinical professor series.

She will support City of Hope’s mission to increase the diversity of clinical faculty, and is responsible for designing, implementing and assessing various programs to address faculty diversity, recruitment, retention and advancement.

Hurria’s goals toward those ends include developing pilot grant awards for junior faculty, organizing a regular meeting for women leaders in the oncology field to share experiences and advice with female faculty, informing faculty of career development opportunities outside City of Hope, and supporting diversity at all levels.

“As the daughter of Indian immigrants and doctors, I am particularly passionate about ensuring that diverse voices are represented at the table,” Hurria said.

“One of the opportunities that truly helped me grow was serving as chair of the ASCO Professional Development Committee, where I was able to strategically plan professional development activities for members. I realized just how many opportunities there are within our own field to help foster the careers of individuals within our own profession. As vice provost, I will work to bring those opportunities to City of Hope and develop programs that can foster the career development for all of our faculty members.”

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login